Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arvinas, Inc. (NASDAQ: ARVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on targeted protein degradation. Arvinas files current reports on Form 8-K, along with periodic reports such as Forms 10-K and 10-Q, to describe material events, financial results and key developments across its PROTAC pipeline.
In its 8-K filings, Arvinas reports items such as quarterly financial results and corporate updates, presentation of clinical and preclinical data for programs including ARV-102 (a PROTAC LRRK2 degrader), ARV-393 (a BCL6 degrader for non-Hodgkin lymphoma) and ARV-806 (a KRAS G12D degrader for solid tumors), and regulatory milestones for vepdegestrant, its investigational PROTAC estrogen receptor degrader for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. The company also uses 8-Ks to disclose collaboration updates with Pfizer, workforce and cost management actions, and Board and executive changes.
Through this page, users can review how Arvinas describes its PROTAC platform, clinical-stage programs and corporate actions in official SEC documents. Real-time updates from EDGAR allow investors to see new 8-Ks and other filings as they are posted, while AI-powered tools on Stock Titan can help summarize lengthy filings, highlight key sections on topics such as clinical data, regulatory status and capital allocation, and surface patterns across multiple ARVN disclosures.
For those researching ARVN, these filings are a primary source for understanding the status of vepdegestrant’s New Drug Application, the design and progress of trials in oncology and neurodegeneration, and the financial and governance information Arvinas reports to regulators and shareholders.
Arvinas, Inc. President and CEO Randy Teel reported equity awards from the company. He received a stock option for 218,691 shares at an exercise price of $0.00 per share and a grant of 147,791 restricted stock units, each settling into one common share if vesting conditions are met. Both awards vest over four years starting on February 12, 2027, contingent on his continued service.
Arvinas, Inc. director John G. Houston reported selling a total of 35,297 shares of common stock on February 27, 2026 in three open‑market transactions at prices between $13.14 and $13.24 per share.
According to the footnotes, each sale was made automatically by Arvinas to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units, and the sales did not represent discretionary trades. After these transactions, Houston directly owned 1,122,183 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock tied to tax withholding. On February 23, he sold 1,108 shares of Arvinas common stock at $12.16 per share. The sale was made by the company to cover tax obligations arising from the vesting and settlement of one-half of his restricted stock units granted on February 23, 2024, and did not represent a discretionary trade. After this transaction, Loomis directly holds 29,692 Arvinas common shares.
ARVINAS, INC. Chief Scientific Officer Angela M. Cacace reported automatic sales of a total of 3,609 shares of common stock at $12.16 per share. These transactions were made by the company to cover tax withholding on vesting restricted stock units and did not represent discretionary trades.
Arvinas, Inc. President and CEO Randy Teel reported two open-market sales of common stock linked to equity award vesting. On February 23, 2026, he sold 1,038 shares and 3,748 shares at $12.16 per share, totaling 4,786 shares.
According to the footnotes, both sales were made automatically by the company to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on February 22, 2023 and February 23, 2024, and do not represent discretionary trades.
Arvinas, Inc. reports a year focused on advancing its PROTAC protein degradation pipeline while remaining deeply loss‑making. The company is still pre‑revenue from product sales and recorded net losses of $80.8 million in 2025, $198.9 million in 2024 and $367.3 million in 2023, and expects operating losses for at least several more years.
Its most advanced candidate, vepdegestrant, has a New Drug Application accepted by the FDA for ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer, with a PDUFA action date of June 5, 2026. Arvinas highlights a broad clinical pipeline, including ARV‑102 for Parkinson’s disease and PSP, ARV‑806 for KRAS G12D‑mutated solid tumors, ARV‑393 for non‑Hodgkin lymphoma and ARV‑027 for spinal bulbar muscular atrophy, plus multiple preclinical neurology, oncology, and immuno‑oncology programs. Management believes existing cash, cash equivalents and marketable securities can fund planned operations into the second half of 2028, but substantial additional capital will ultimately be required.
Arvinas, Inc. reported 2025 results showing a sharply reduced net loss and a stronger balance sheet to support its PROTAC pipeline. Full-year revenue was $262.6 million, roughly flat with 2024, while the net loss narrowed to $80.8 million from $198.9 million as both R&D and G&A expenses declined.
Year-end cash, cash equivalents and marketable securities totaled $685.4 million, and the company expects this to fund operations into the second half of 2028. Arvinas highlighted multiple clinical programs, including ARV-102, ARV-806, ARV-393, ARV-027 and ARV-6723, as well as vepdegestrant, which has an FDA PDUFA action date of June 5, 2026.
The company also appointed Randy Teel, Ph.D., as President and CEO, continued progressing four ongoing clinical trials, initiated a Phase 1 study for ARV-027, and prepared to move its first immuno-oncology candidate ARV-6723 into the clinic, underscoring an active late- and mid-stage pipeline.
Arvinas, Inc. submitted a Form 144 notifying the proposed sale of 3,609 shares of common stock in connection with the settlement of vested restricted stock units on 02/23/2026. The filing also reports a prior sale of 4,592 shares on 02/13/2026. The broker listed is Morgan Stanley Smith Barney LLC.
Arvinas, Inc. filed a notice for the proposed sale of 4,786 common shares through Morgan Stanley Smith Barney LLC, reflecting the settlement of vested restricted stock units on 02/23/2026.
The filing also reports an earlier sale by Randy Teel of 4,403 common shares on 02/13/2026 for $52,359.96.